remained. He was discharged from hospital without continuing treatment. Two weeks later he developed severe deep otalgia and an increased blood glucose concentration. Repeat computed tomography showed more extensive temporal bone erosion. Intravenous ceftazidime wjas given for two weeks followed by oral ciprofloxacin 500 mg twice a day for three months as outpatient treatment. He steadily improved, and the facial palsy resolved almost completely. The vagal and hypoglossal palsies remained, but there was good functional compensation. He subsequently remained well 22 months after completing treatment.
Athletes and drugs SIR,-Dr Richard Feinmann's recent letter shows the widespread confusion about drug use in sport, within the sporting world and the medical profession.
In the example Dr Feinmann gave two of the athletes were "not allowed to take any medication" for hay fever. The Scottish Sports Council's recommendations for hay fever, however, permit inhaled steroids (beclomethasone dipropionate), several antihistamines (terfenadine, chloropheniramine maleate, etc) and sodium cromoglycate eye drops. 2 We assume that all the sports bodies in the United Kingdom have similar guidelines.
It is unfortunate that all concerned in sporting events are not aware of the permitted treatments. We suggest that such information be widely distributed to all those in sport. In addition, it should be readily available to doctors so that appropriate treatment can be prescribed to athletes. A suitable place might be at the end of the British National Formulary in a separate appendix or in the "cautionary label" warnings. ' Lambasted on heart disease SIR, -In reporting the verdict of the Committee of Public Accounts on Britain's attempts to reduce coronary mortality Dr Tessa Richards states that in Scotland there is a lack of any campaign tackling the problem of heart disease.' This is inaccurate.
In December 1988, amid much publicity, SHARP (Scottish Heart and Arterial disease Risk Prevention) was launched at an international symposium on coronary risk factors. This organisation has been established to tackle Scotland's deplorable record of coronary morbidity and mortality and its main aim is to promote the prevention of cardiovascular diseases in primary care, in hospital practice, and in the community. Several major projects will soon be announced, but much of the resources of time, energy, and skill of the committee has initially had to be diverted to seeking financial support. So far all funding has come from pharmaceutical companies.
Dr Richards points out that £LOm is spent on prevention while £500m is spent on treating cardiovascular diseases. If organisations such as SHARP were to be properly funded not only could the latter figure be drastically reduced but also the emotional and economic devastation to individual patients and families affected by cardiovascular diseases could be alleviated. the stent and the other being six weeks after implantation in a patient with advanced adenocarcinoma of the prostate. In both cases the stent was removed by grasping it under endoscopic control with alligator forceps and applying distal traction, thereby elongating the stent and reducing its diameter. In neither case did any urethral trauma result. To our knowledge a further three Wallstents have been removed without difficulty in other centres. Although it is still too early to comment definitively on the use of this stent technique in managing prostate obstruction (owing to the short follow up time and small number of patients so far treated), we believe that it merits further consideration. Certainly the ability to remove these stents is of fundamental importance, and a potential application is the use of such stents to relieve obstruction due to the prostate on a trial basis in patients in whom dual pathology is suspected. The stent could then either be left in situ or be removed before a definitive transurethral prostatectomy. Topical homatropine also has been reported to cause confusion in an elderly man. 4 An 84 year old woman was admitted to our wards after an episode of dizziness and palpitations culminating in virtual syncope. tier radial pulse rate was initially 160-180 beats/min but settled spontaneously to a rate of 80 beats/min. Physical examination showed partial blindness due to cataract and glaucoma, for which she was receiving topical homatropine eyedrops. She was taking no other medication and her only additional relevant history was of several similar episodes of palpitations and lightheadedness over the preceding four months. These attacks occurred in the morning or evening within an hour of instilling the drops, though she had been taking homatropine for about two years. Routine biochemical, haematological, and thyroid function tests; chest x ray film; and resting and 24 hour electrocardiograms were all normal. Homatropine was discontinued and she remained well when reviewed two and four months after discharge with no further symptoms suggestive of an arrhythmia. Rechallenge with homatropine was considered unethical.
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Although possibly coincidental, the administration of homatropine eyedrops, at recommended therapeutic doses, seemed to precipitate tachycardia in this otherwise fit, elderly woman Case 3-In 1987 a 64 year old Australian woman started to take diltiazem 30 mg three times a day for angina. After three days she developed insomnia and depression characterised by early morning waking and morbid thoughts. These symptoms persisted for 41 days, until she stopped taking diltiazem and recovered. She had been taking, and continued to take, one naproxen tablet daily for arthritis. About 10 days later she again started taking diltiazem, 90 mg daily, and the depression returned within two weeks. Recovery followed within a few days of stopping the drug.
Cases 4-9 -Details are set out in the table. Calcium channel blocking drugs are customarily classified in four groups, reflecting their chemical structures. The piperazine group, which includes cinnarizine and flunarizine, has adverse effects strongly suggestive of a direct action on the central nervous system. Extrapyramidal symptoms and depression are well documented with flunarizine. 2 Members of the other groups -phenylalkylamines (verapamil), dihydropyridines (nifedipine, felodipine, and nicardipine), and benzothiazepines (diltiazem)-have been used to treat neurological disorders including migraine,' Gilles de la Tourette's syndrome,4 tardive dyskinesia and dystonia,9 and some psychiatric disorders. Verapamil, in particular, has been used to treat mania." However, evidence of direct adverse effects on the central nervous system is meagre. Single case reports have attributed akathisial and acute psychosis9 to diltiazem and acute psychosis to nifedipine.'°0' Recently four cases of substantial depression associated with nifedipine were reported. I2 Spontaneous reports of suspected adverse reactions submitted to national centres often lack important information. None the less, we believe that these case reports show that diltiazem can cause depression. Cases 1 and 5 suggest that depression caused by diltiazem can be severe and may be accompanied by other symptoms. The latency ofonset in these cases ranged from less than a day to one to two months. There was a positive rechallenge in two cases.2 In five of the eight cases the daily dose was 180 mg or more, and the pattern in case 4 suggested a dose related effect. 
MMR and the nephrotic syndrome
) write: In 1969 one of us (ASA) looked after a young child who developed the nephrotic syndrome two weeks after measles immunisation. In 1972 three cases of the nephrotic syndrome after measles vaccination were reported.' As yet
